SOURCE: Envita Medical Center

Envita Medical Center

October 26, 2015 19:24 ET

Powerful Envita Video Shows How Genetically Targeted Fractionated Chemotherapy Can Help Improve Cancer Treatment Success

SCOTTSDALE, AZ--(Marketwired - October 26, 2015) - A new video has emerged that might just show why chemotherapy may not be working as well as hoped. It features a targeted alternative to standard chemotherapy that is now being introduced by Dr. Dino Prato and his team of physicians at Envita Medical Center. The powerful treatment is called GTFC, or Genetically Targeted Fractionated Chemotherapy, and it is based on targeting biomarkers, specific information encoded within cancer cells. These biomarkers can help determine the most effective drugs and treatments for a patient’s specific cancer diagnosis. Because of GTFC’s fractionated and targeted approach, more therapeutic targets are utilized, thereby leading to a greatly reduced toxicity factor, as well as reduced side effects for patients. Currently, Envita is finding targets and viable treatment options for patients that were sent home by their oncologists to die.

Before GTFC can be administered, patients must go through a rigorous form of testing. According to the video, because cancer grows and spreads through circulating tumor cells that travel all throughout the body, the doctors at Envita use a blood draw to capture real time information from these circulating tumor cells, and not just the tumor biopsy. Dino Prato, the founder and CEO of Envita, explains the reasoning behind using circulating tumor cells: “We have had some patients respond to chemotherapy for a time but the drug that was used will sometimes stop working. We soon found that this happens when the biomarkers that were present at the time of the original biopsy were no longer present. That is why real time biomarker testing of the circulating tumor cells is so crucial for patients.” Centers that use just the tumor biopsy are many times relying on outdated information and this can hamper effective treatment.

After the most recent and real time data is made available, GTFC is poised to attack multiple targets. This is made possible due to the metronomic dosing (low dose, equally spacing intervals) inherent in GTFC, which allows patients to receive multiple drugs that may work on several different biomarkers (including up to 7-10 targets). Attacking numerous targets with different drugs has the ability to increase a cancer patient’s odds of killing cancer cells. In comparison, standard chemotherapy can only target 1 or 2 biomarkers because of the toxicities inherent in the maximum dose method.

Patients and doctors are hailing treatments like GTFC as the new future of chemotherapy and the dawn of precision medicine. The days of maximum dose chemotherapy and the painful side effects that come with it may soon be over.

Visit www.envita.com or contact marshalla@envita.com for more information. To view the complete GTFC video on YouTube, go here.

Image Available: http://www.marketwire.com/library/MwGo/2015/10/26/11G069122/Images/genetically_targeted_fractionated_chemotherapy-1119215619595.jpg

Embedded Video Available: https://www.youtube.com/watch?v=bZWhjux2b0M

Contact Information